Alpha-2A, Alpha-2B, and Alpha-2C adrenergic receptor (α2A/2B/2C AR (or ADRA2A/ADRA2B/ADRA2C for gene/protein-specific cases))

The Alpha-2A, Alpha-2B, and Alpha-2C adrenergic receptors are closely related subtypes of G protein-coupled receptors that bind the endogenous catecholamines norepinephrine and epinephrine and regulate the sympathetic nervous system both centrally and peripherally[5][1][9][4]. The subtypes differ in tissue distribution and physiological roles: - Alpha-2A regulates neurotransmitter release at high-frequency stimulation, is predominant in CNS inhibition of norepinephrine release, and is a key target for antihypertensives and sedatives[5][1][3]. - Alpha-2B is expressed mainly in peripheral vasculature and mediates vasoconstrictive responses. - Alpha-2C modulates neurotransmitter release during lower levels of stimulation and plays roles in stress response and cognitive function[5]. Many drugs act as agonists or antagonists at these sites for indications such as hypertension, attention-deficit hyperactivity disorder, anesthetic adjunct (sedation/analgesia), withdrawal syndromes, and some eye diseases[2][8][4]. Adverse effects result mainly from excessive reduction in sympathetic tone. These receptors are well-validated molecular targets but should ideally be treated individually in structured data systems rather than as a combined group.

Other names

Alpha-2 adrenergic receptorα2-adrenergic receptorAdrenoceptor alpha 2A/B/CADRA2AADRA2BADRA2C

Agonists stimulate presynaptic α2-adrenergic receptors, inhibiting norepinephrine release in the CNS, resulting in decreased sympathetic outflow, vasodilation, reduced peripheral resistance, and lowered blood pressure - Antagonists inhibit these receptors, promoting neurotransmitter release and increased sympathetic activity